阿拉丙酯

**阿拉丙酯**
臨床資料
给药途径	Oral
ATC碼	N06AB07 (WHO) ;
法律規範狀態
法律規範	Uncontrolled;
识别
	IUPAC命名法 1-(4-Chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate; ;
CAS号	60719-82-6（; 60719-83-7 (hydrochloride)）
PubChem CID	2081;
ChemSpider	1997 ;
UNII	C4R42570ZO;
KEGG	D02787 ;
ChEMBL	ChEMBL36591 ;
CompTox Dashboard (EPA)	DTXSID5045122 ;
化学
化学式	C13H18ClNO2
摩尔质量	255.74 g·mol−1
3D模型（JSmol）	交互式图像;
	SMILES Clc1ccc(cc1)CC(OC(=O)C(N)C)(C)C;
	InChI InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3 ; Key:FZSPJBYOKQPKCD-UHFFFAOYSA-N ;

阿拉丙酯（英语：Alaproclate；开发代号：GEA-654）是瑞典制药公司Astra AB（现为阿斯利康）在1970年代开发的一种抗抑郁药物。它作为一种选择性血清素再摄取抑制剂（SSRI），与齐美利定和吲达平一起，是同类药物中最早的一种。由于在啮齿动物研究中观察到肝脏并发症，开发被终止开发。除了其SSRI特性外，阿拉丙酯还被发现可作为非竞争性NMDA受体拮抗剂，但不具有类似于苯环己哌啶的区分刺激特性。[1][2]

合成

老年痴呆症的治疗方法：[3]

合成：[4]专利：[5]放射性标记：[6][7]

4-氯苯乙酸甲酯 (1) 与甲基碘化镁之间的格氏反应可得到1-(4-氯苯基)-2-甲基-2-丙醇 (2)。(2)与2-溴丙酰溴 (3)酰化得到[1-(4-氯苯基)-2-甲基丙-2-基]2-溴丙酸酯 (3)，CID:13695101。用氨取代卤素得到丙丙酸 (4)。

参见

非莫西汀
吲达平
齐美利定

参考资料

Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE. . The Journal of Pharmacology and Experimental Therapeutics. December 1994, 271 (3): 1314–9. PMID 7996440.
Nicholson KL, Balster RL. . Psychopharmacology. November 2003, 170 (2): 215–24. PMID 12851738. S2CID 30803162. doi:10.1007/s00213-003-1527-6.
Ulf H. A. Lindberg, Sven-Ove gren, 美國專利第4,469,707号 (1984 to Astra Lakemedel Aktiebolag).
Lindberg, Ulf Henrik (1978). "Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by .alpha.-amino acid esters of phenethyl alcohols". Journal of Medicinal Chemistry 21 (5): 448–456. doi:10.1021/jm00203a008.
Ulf M. A. Lindberg, Svante B. Ross, Seth-Olov Thorberg, Sven O. / gren, 美國專利第4,237,311号 & 美國專利第4,331,684号 (1980 & 1982 both to Astra Lakemedel Aktiebolag).
Gawell, Lars (1986). "Synthesis of [14C]alaproclate". Journal of Labelled Compounds and Radiopharmaceuticals. 23 (9): 947–949. doi:10.1002/jlcr.2580230905.
Bengtsson, Stefan; Gawell, Lars; Högberg, Thomas; Sahlberg, Christer (1985). "Synthesis and 3H NMR of 3H-alaproclate of high specific activity". Journal of Labelled Compounds and Radiopharmaceuticals. 22 (5): 427–435. doi:10.1002/jlcr.2580220503.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE. . The Journal of Pharmacology and Experimental Therapeutics. December 1994, 271 (3): 1314–9. PMID 7996440.

[2] Nicholson KL, Balster RL. . Psychopharmacology. November 2003, 170 (2): 215–24. PMID 12851738. S2CID 30803162. doi:10.1007/s00213-003-1527-6.

[3] Ulf H. A. Lindberg, Sven-Ove gren, 美國專利第4,469,707号 (1984 to Astra Lakemedel Aktiebolag).

[4] Lindberg, Ulf Henrik (1978). "Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by .alpha.-amino acid esters of phenethyl alcohols". Journal of Medicinal Chemistry 21 (5): 448–456. doi:10.1021/jm00203a008.

[5] Ulf M. A. Lindberg, Svante B. Ross, Seth-Olov Thorberg, Sven O. / gren, 美國專利第4,237,311号 & 美國專利第4,331,684号 (1980 & 1982 both to Astra Lakemedel Aktiebolag).

[6] Gawell, Lars (1986). "Synthesis of [14C]alaproclate". Journal of Labelled Compounds and Radiopharmaceuticals. 23 (9): 947–949. doi:10.1002/jlcr.2580230905.

[7] Bengtsson, Stefan; Gawell, Lars; Högberg, Thomas; Sahlberg, Christer (1985). "Synthesis and 3H NMR of 3H-alaproclate of high specific activity". Journal of Labelled Compounds and Radiopharmaceuticals. 22 (5): 427–435. doi:10.1002/jlcr.2580220503.